Question 1

A defect in production of cryopyrin leads to:

Accepted Answer

A)  Increased synthesis of IL-2 
B)  Increased synthesis of TNF 
C)  Increased synthesis of IL-1b 
D)  Increased synthesis of IL-1a 
A)  Increased synthesis of IL-2 
B)  Increased synthesis of TNF 
C)  Increased synthesis of IL-1b 
D)  Increased synthesis of IL-1a C

Question 2

Which is one disadvantage to cell-based anticancer vaccines?

Accepted Answer

A)  Vaccines often must be patient-specific. 
B)  Vaccines may react with other host cells. 
C)  Vaccines with live cells do not have long-lasting effects. 
D)  Vaccines are less effective because they use allogeneic cells. 
A)  Vaccines often must be patient-specific. 
B)  Vaccines may react with other host cells. 
C)  Vaccines with live cells do not have long-lasting effects. 
D)  Vaccines are less effective because they use allogeneic cells. A

Question 3

NY-ESO-1 would be a beneficial addition to a cancer vaccine because:

Accepted Answer

A)  It stimulates macrophages 
B)  It stimulates the production NK cells 
C)  It stimulates both CD4 and CD8 T cells 
D)  It stimulates a strong antibody response 
A)  It stimulates macrophages 
B)  It stimulates the production NK cells 
C)  It stimulates both CD4 and CD8 T cells 
D)  It stimulates a strong antibody response C

Question 4

What is the mechanism of action of the sipuleucel-T prostate cancer vaccine?

Accepted Answer

A)  Dendritic cells are incubated with a fusion protein containing prostate specific antigen (PS
A)  and GM-CSF. 
B)  A plasmid that codes for an antibody that expresses prostate specific antigen (PS
A) , and dendritic cells present PSA to T cells. 
C)  A single B cell clone that is tumor specific is grown in the lab and infused into the patient to produce large amounts of tumor specific antibody. 
D)  Patient tumor cells are exposed to a viral vector containing a gene for prostate specific antigen (PS
A) , and then the tumor cells are infused into the patient to stimulate an immune response. 
A)  Dendritic cells are incubated with a fusion protein containing prostate specific antigen (PS
A)  and GM-CSF. 
B)  A plasmid that codes for an antibody that expresses prostate specific antigen (PS
A) , and dendritic cells present PSA to T cells. 
C)  A single B cell clone that is tumor specific is grown in the lab and infused into the patient to produce large amounts of tumor specific antibody. 
D)  Patient tumor cells are exposed to a viral vector containing a gene for prostate specific antigen (PS
A) , and then the tumor cells are infused into the patient to stimulate an immune response.

Question 5

Which of the following is a marker for melanoma?

Accepted Answer

A)  AFP 
B)  CEA 
C)  MART-1 
D)  Sialyl Tn antigen 
A)  AFP 
B)  CEA 
C)  MART-1 
D)  Sialyl Tn antigen

Question 6

Which of the following is an outcome of IL-1 release from activated immune cells?

Accepted Answer

A)  Cleavage of viral RNA 
B)  Prevention of microbial growth 
C)  Increased production of antibodies 
D)  Downregulation of adhesion molecules 
A)  Cleavage of viral RNA 
B)  Prevention of microbial growth 
C)  Increased production of antibodies 
D)  Downregulation of adhesion molecules

Question 7

Oprelvekin increases levels of:

Accepted Answer

A)  Platelets 
B)  Neutrophils 
C)  Macrophages 
D)  Red blood cells 
A)  Platelets 
B)  Neutrophils 
C)  Macrophages 
D)  Red blood cells

Question 8

What is one role that type I interferons play in the eradication of viral infections?

Accepted Answer

A)  Inhibit viral uncoating 
B)  Inhibit viral protein synthesis 
C)  Block viral entry into host cells 
D)  Block release of viral progeny from host cells 
A)  Inhibit viral uncoating 
B)  Inhibit viral protein synthesis 
C)  Block viral entry into host cells 
D)  Block release of viral progeny from host cells

Question 9

Which of the following may be administered to treat rheumatoid arthritis? 
I. Infliximab
II. Adalimumab
III. Canakinumab

Accepted Answer

A)  I only 
B)  III only 
C)  I and II 
D)  II and III 
E)  I, II, and III 
A)  I only 
B)  III only 
C)  I and II 
D)  II and III 
E)  I, II, and III

Question 10

Recombinant IL-2 administration is appropriate for the treatment of:

Accepted Answer

A)  HIV 
B)  Cancer 
C)  Arthritis 
D)  Transplant patients 
A)  HIV 
B)  Cancer 
C)  Arthritis 
D)  Transplant patients

A defect in production of cryopyrin leads to:

Which is one disadvantage to cell-based anticancer vaccines?

NY-ESO-1 would be a beneficial addition to a cancer vaccine because:

What is the mechanism of action of the sipuleucel-T prostate cancer vaccine?

Which of the following is a marker for melanoma?

Which of the following is an outcome of IL-1 release from activated immune cells?

Oprelvekin increases levels of:

What is one role that type I interferons play in the eradication of viral infections?

Which of the following may be administered to treat rheumatoid arthritis? I. Infliximab II. Adalimumab III. Canakinumab

Recombinant IL-2 administration is appropriate for the treatment of:

Cells and Organs of the Immune System

Innate Immunity

Immunogenicity and Antigenicity

Antigen Presenting Molecules

Antigen Presenting Cells

Surface Interactions Between T Cells and Antigen-Presenting Cells

Intracellular Signaling and T Cell Activation

B Cell Activation and Signaling

Antibodies

Antibody Diversity

Complement

Phagocytosis and Intracellular Killing

Antibodies and in Vivo Therapy

Antibodies and in Vitro Research and Diagnostic Assays

Immediate Allergic Reactions

Autoimmunity

Transplantation

Antigen Presentation for Cell-Mediated Response

Delayed Type Hypersensitivity Reactions

Cytotoxic T Cells

Natural Killer Cells

Factors That Influence the Immune Response

Vaccines in Theory and Practice

Vaccine-Preventable Diseases

Acquired Immune Deficiency Syndrome

Filters

Exam 23: Cytokines and Biological Modifiers

A defect in production of cryopyrin leads to:

Which is one disadvantage to cell-based anticancer vaccines?

NY-ESO-1 would be a beneficial addition to a cancer vaccine because:

What is the mechanism of action of the sipuleucel-T prostate cancer vaccine?

Which of the following is a marker for melanoma?

Which of the following is an outcome of IL-1 release from activated immune cells?

Oprelvekin increases levels of:

What is one role that type I interferons play in the eradication of viral infections?

Which of the following may be administered to treat rheumatoid arthritis? I. Infliximab II. Adalimumab III. Canakinumab

Recombinant IL-2 administration is appropriate for the treatment of:

Cells and Organs of the Immune System

Innate Immunity

Immunogenicity and Antigenicity

Antigen Presenting Molecules

Antigen Presenting Cells

Surface Interactions Between T Cells and Antigen-Presenting Cells

Intracellular Signaling and T Cell Activation

B Cell Activation and Signaling

Antibodies

Antibody Diversity

Complement

Phagocytosis and Intracellular Killing

Antibodies and in Vivo Therapy

Antibodies and in Vitro Research and Diagnostic Assays

Immediate Allergic Reactions

Autoimmunity

Transplantation

Antigen Presentation for Cell-Mediated Response

Delayed Type Hypersensitivity Reactions

Cytotoxic T Cells

Natural Killer Cells

Factors That Influence the Immune Response

Vaccines in Theory and Practice

Vaccine-Preventable Diseases

Acquired Immune Deficiency Syndrome

Filters